PMC4722092_01
Computed tomography (CT) images after treatment with two cycles of gemcitabine and four cycles of the combination of carboplatin and nanoparticle albumin-bound paclitaxel (nabPC). A-C show disease progression after the treatment with gemcitabine. D-F show a drastic decrease in tumor volume after the treatment with nabPC.
RCR2-4-28-g001.jpg
PMC4722092_01_RCR2-4-28-g001.jpg
rcr2145-fig-0001
A CT scan taken after two cycles of gemcitabine demonstrated tumor progression (Fig. 1A-C). Drastic decreases in interlobular nodules and pleural thickness were achieved (Fig. 1D-F) Repeated administration of nab-paclitaxel worsened the patient's peripheral sensory neuropathy, resulting in withdrawal of the chemotherapy by the fourth cycle.
CT images before and after rechallenge with four cycles of nabPC. A-C show disease progression after the first treatment with nabPC. D-F show a modest response after rechallenge with nabPC.
RCR2-4-28-g003.jpg
PMC4722092_01_RCR2-4-28-g003.jpg
rcr2145-fig-0002
A chest CT performed 2 months later confirmed an increase in pleural thickness and interlobular nodules due to disease progression (Fig. 2A-C). A modest decrease in pleural thickness and interlobular nodules was achieved without any grade 3/4 hematological adverse effects (Fig. 2D-F).